lipodystrophy - Robuta Search

https://boris-portal.unibe.ch/entities/publication/677c9677-560e-4040-81e7-853250228fb1 Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006 BACKGROUND AND OBJECTIVES: Combination antiretroviral therapy (cART) is changing, and this may affect the type and occurrence of side effects. We examined the... https://pubmed.ncbi.nlm.nih.gov/35137140/ Approach to the Patient With Lipodystrophy Lipodystrophy constitutes a spectrum of diseases characterized by a generalized or partial absence of adipose tissue. Underscoring the role of healthy fat in... to the approach patient lipodystrophy https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=234&fromTracking=Y&fromdb=true NCA - Dermal injections for the treatment of facial lipodystrophy syndrome (FLS) (CAG-00412N) -... Use this page to view details for the decision Memo for Dermal injections for the treatment of facial lipodystrophy syndrome (FLS) (CAG-00412N). https://iris.cnr.it/handle/20.500.14243/159236 Altered pre-lamin A processing is a common mechanism leading to lipodystrophy, altered pre lamin processing https://www.niddk.nih.gov/news/archive/2015/leptin-treatment-generalized-lipodystrophy Leptin as a treatment for generalized lipodystrophy: a translational success story - NIDDK The hormone leptin is approved to treat lipodystrophy, a lack of body fat. Leptin can improve insulin sensitivity and fat metabolism in lipodystrophy patients. as a treatment for success story leptin https://research.manchester.ac.uk/en/publications/hiv-associated-lipodystrophy-a-review-of-underlying-mechanisms-an/ HIV-associated lipodystrophy: A review of underlying mechanisms and therapeutic options - Research... a review https://pubmed.ncbi.nlm.nih.gov/40759924/ Preclinical evaluation of candidate "kill or cure" strategies to treat MFN2-related lipodystrophy Ethanol mildly exacerbates murine MFN2-related MSL, while rapamycin is tolerated. MFN2-related MSL may not be solely attributable to compromised oxidative... https://pubmed.ncbi.nlm.nih.gov/17325275/?dopt=Abstract&holding=idemdclib_fft&otool=idemdclib Muscle and nerve pathology in Dunnigan familial partial lipodystrophy The myopathy and neuropathy associated with Dunnigan familial partial lipodystrophy are distinct from other lamin A/C disorders. We hypothesize that the... muscle nerve pathology dunnigan familial https://rarediseases.info.nih.gov/diseases/3126/familial-partial-lipodystrophy-dunnigan-type Familial partial lipodystrophy, Dunnigan type | About the Disease | GARD Find symptoms and other information about Familial partial lipodystrophy, Dunnigan type. about the disease familial partial lipodystrophy dunnigan https://agris.fao.org/search/en/providers/123819/records/6473637e2c1d629bc97f6954 Familial partial lipodystrophy: complications of obesity in the non-obese? in the familial partial lipodystrophy complications https://www.semanticscholar.org/topic/Familial-Partial-Lipodystrophy%2C-Type-3/1543923 Familial Partial Lipodystrophy, Type 3 | Semantic Scholar This type can be caused by mutation in the gene encoding PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA. familial partial lipodystrophy type semantic